Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:43:23.916Z.
Calculation as of: 2026-10-06T20:43:23.916Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9ce6fbcd26cd45408ca5c48bb89acec7413e4f513cf2411d103b895814b8ecfc
PE RATIO
N/A
Market Cap
$1.83B
PE Ratio
N/A
TTM Avg
625.71
3Y Avg
635.68
5Y Avg
635.68
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Trevi Therapeutics, Inc. (TRVI) | $1.87B | N/A | N/A | N/A | N/A |
| Novavax, Inc. (NVAX)vs › | $1.86B | N/A | 3.65 | 3.65 | 3.65 |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 37.72 | 35.65 | 35.65 | 327.33 |
| Zymeworks Inc. (ZYME)vs › | $1.89B | N/A | 3.35 | 3.35 | 3.35 |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | N/A | 3.28 | 3.28 | 3.28 |
| Immunome, Inc. (IMNM)vs › | $1.85B | N/A | N/A | N/A | N/A |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.84B | N/A | N/A | N/A | N/A |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 45.26 | 79.20 | 49.35 | 42.48 |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.83B | N/A | 625.71 | 635.68 | 635.68 |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.92B | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$13.18
Forward EPS (Est.)
$-0.48
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
